Prospective, Multi-Center, Observational Program to Assess RSV Hospitalization Rate in Population of Children at High-risk of Serious RSV Illness Who Received Palivizumab Immunoprophylaxis in Routine Clinical Setting in the Russian Federation
Phase of Trial: Phase IV
Latest Information Update: 04 Jul 2016
At a glance
- Drugs Palivizumab (Primary)
- Indications Respiratory syncytial virus infections
- Focus Therapeutic Use
- Acronyms SUNRISE
- Sponsors AbbVie
- 05 Jun 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov record.
- 18 Mar 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 10 Nov 2014 New trial record